European Leukemia Trial Registry
Trial: PAZOPANIB-AML

More Details
Title Pazopanib in Relapsed or Refractory AML or at Initial Diagnosis When no Intensive Treatment is Possible
Scientific Title Phase II Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible
Short Title PAZOPANIB-AML
Trialgroup NN
Type of Trial single-group, prospective, open-label, monocentic
Disease Acute myeloid leukemia(AML) AML all subtypes without FAB M3
Age >= 18 years
Status Closed
Start of Recruitment 10.04.2013
Leader Keßler, PD Dr. med., Torsten
Contactperson

General Contact Person
Koschmieder, Prof. Dr. med., Steffen
Tel: +49 (0)241 8036102
Fax: +49 (0)241 8082449
Email: skoschmieder@ukaachen.de

Shortprotocol Shortprotocol
created 10.04.2013 Johannes Kraus
changed 16.02.2017 Eva-Maria Ableidinger
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org